RDEA806

RDEA896 is a new NNRTI, developed by Ardea Biosciences, with a high barrier to resistance against the common mutations that develop with efavirenz and nevirapine.

A phase II, multicentre dose-ranging study of this drug is currently enrolling ARV-naive patients in Europe. The proof-of-concept monotherapy study of this drug in ARV-naive patients showed a minimum one log decline in viral load with no evidence of rash or central nervous system side-effects such as those found in EFV.1

References

  1. Moyle G et al. Antiviral activity of REDA806, a novel HIV non-nucleoside reverse transciptase inhibitor in treatment naive HIV patients. 17th International AIDS Conference, Mexico City, THAB0403, 2008
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.